


# Clinical trial: New combination treatment for eye melanoma increased patient survival

August 27 2021



Immune profiles of pre- and post-treatment (one cycle) blood samples. a–c Flow cytometry analyses of changes in circulating cell populations in shorter and longer survivors following treatment with entinostat and pembrolizumab. Gating strategies can be found in Supplementary Fig. 5. (a) Graphs showing the frequency of CD3 + lymphocytes (left), CD14 + monocytes (middle), and CD33 + neutrophils (right) among patients with shorter ( $n = 12$ ) and (b) longer ( $n = 12$ ) survival prior to (circles) or after (squares) one cycle of treatment. (c) Analysis of CD8 + cytotoxic T cells in patients with shorter and longer survival. Statistical analysis was performed using multiple paired t-tests correct for multiple comparisons using a two-stage step-up (Benjamini, Krieger, and Yekutieli) with test between all groups in (a–b), where \* indicates adjusted p-values

Citation: Clinical trial: New combination treatment for eye melanoma increased patient survival (2021, August 27) retrieved 29 March 2023 from

<https://medicalxpress.com/news/2021-08-clinical-trial-combination-treatment-eye.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.